# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimat...
Maxim Group analyst Jason McCarthy initiates coverage on NeuroBo Pharmaceuticals (NASDAQ:NRBO) with a Buy rating and announc...
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometa...
https://www.sec.gov/Archives/edgar/data/1638287/000155837024005018/tmb-20240412xs3.htm
On March 1, 2024, the Board of Directors (the “Board”) of NeuroBo Pharmaceuticals, Inc. (the “Company”) appointed Mr. Marshall ...